Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Chief Financial Officer and VP | February 14, 2020 | February 19, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Spyre Therapeutics, Inc.
Report date February 14, 2020 · Filed February 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2030-02-13 | Direct | 126,000 |
Reported balance
After 2020-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-14 · Grant · Acquired 126,000 · Balance 126,000 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 14, 2020, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 14, 2020, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Day One Biopharmaceuticals, Inc.
Report date April 23, 2026 · Filed April 23, 2026
Section 16 reporting ended · disclosed 2026-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Disposition to issuer · Disposed 312,025 · Balance 0 F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2031-05-25 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-23 · Disposition to issuer · Disposed 497,667 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3: The options are fully vested. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2032-01-17 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-23 · Disposition to issuer · Disposed 151,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5: The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2033-01-16 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-23 · Disposition to issuer · Disposed 116,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F6: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2034-01-04 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-23 · Disposition to issuer · Disposed 162,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2035-01-14 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-23 · Disposition to issuer · Disposed 162,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F8: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2036-01-29 | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-23 · Disposition to issuer · Disposed 188,000 · Balance 0 F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F9: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-23 · Disposition to issuer · Disposed 6,750 · Balance 0 F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-23 · Disposition to issuer · Disposed 46,375 · Balance 0 F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-23 · Disposition to issuer · Disposed 72,875 · Balance 0 F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-23 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-04-23 · Disposition to issuer · Disposed 118,125 · Balance 0 F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F13: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.
F3: The options are fully vested.
F4: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.
F5: The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F6: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F7: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F8: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F9: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F10: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F11: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F12: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.
F13: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2026 Filed Apr 23, 2026 20:39 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerRestricted Stock Unit (RSU) · Derivative | 118,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-26-000005 · form4-04232026_080401.xml · derivative · entry 11 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 118,125 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F13 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:39 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerRestricted Stock Unit (RSU) · Derivative | 72,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-26-000005 · form4-04232026_080401.xml · derivative · entry 10 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,875 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:39 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerRestricted Stock Unit (RSU) · Derivative | 46,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-26-000005 · form4-04232026_080401.xml · derivative · entry 9 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,375 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:39 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerRestricted Stock Unit (RSU) · Derivative | 6,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-26-000005 · form4-04232026_080401.xml · derivative · entry 8 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,750 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F11 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:39 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 188,000 | Not disclosed Strike: $11.16 | Not disclosed |
DisclosureSEC source: 0001655962-26-000005 · form4-04232026_080401.xml · derivative · entry 7 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 188,000 shares Expires 2036-01-29 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F9 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:39 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 162,000 | Not disclosed Strike: $8.99 | Not disclosed |
DisclosureSEC source: 0001655962-26-000005 · form4-04232026_080401.xml · derivative · entry 6 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 162,000 shares Expires 2035-01-14 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F8 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:39 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 162,000 | Not disclosed Strike: $8.99 | Not disclosed |
DisclosureSEC source: 0001655962-26-000005 · form4-04232026_080401.xml · derivative · entry 5 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 162,000 shares Expires 2034-01-04 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F7 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:39 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 116,000 | Not disclosed Strike: $8.99 | Not disclosed |
DisclosureSEC source: 0001655962-26-000005 · form4-04232026_080401.xml · derivative · entry 4 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 116,000 shares Expires 2033-01-16 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F6 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:39 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 151,000 | Not disclosed Strike: $8.99 | Not disclosed |
DisclosureSEC source: 0001655962-26-000005 · form4-04232026_080401.xml · derivative · entry 3 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 151,000 shares Expires 2032-01-17 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F5 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:39 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 497,667 | Not disclosed Strike: $8.99 | Not disclosed |
DisclosureSEC source: 0001655962-26-000005 · form4-04232026_080401.xml · derivative · entry 2 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 497,667 shares Expires 2031-05-25 F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| April 23, 2026 Filed Apr 23, 2026 20:39 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerCommon Stock | 312,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-26-000005 · form4-04232026_080401.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 22:16 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 6,065 | $11.60 | $70,359.46 |
DisclosureSEC source: 0001655962-26-000004 · form4-02182026_100206.xml · nonDerivative · entry 5 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,025 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $11.195 to $11.8508, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 22:16 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001655962-26-000004 · form4-02182026_100206.xml · derivative · entry 9 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,125 Underlying: Common Stock · 7,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 22:16 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001655962-26-000004 · form4-02182026_100206.xml · derivative · entry 8 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,875 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 22:16 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001655962-26-000004 · form4-02182026_100206.xml · derivative · entry 7 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,375 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 22:16 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001655962-26-000004 · form4-02182026_100206.xml · derivative · entry 6 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 22:16 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 7,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-26-000004 · form4-02182026_100206.xml · nonDerivative · entry 4 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 22:16 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 6,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-26-000004 · form4-02182026_100206.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 22:16 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 6,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-26-000004 · form4-02182026_100206.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 22:16 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-26-000004 · form4-02182026_100206.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 30, 2026 Filed Jan 30, 2026 22:19 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantRestricted Stock Units · Derivative | 126,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001655962-26-000002 · form4-01302026_100151.xml · derivative · entry 2 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| January 30, 2026 Filed Jan 30, 2026 22:19 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 188,000 | $0.00 Strike: $11.16 | $0.00 |
DisclosureSEC source: 0001655962-26-000002 · form4-01302026_100151.xml · derivative · entry 1 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,000 Underlying: Common Stock · 188,000 shares Expires 2036-01-29 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 00:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 4,062 | $8.91 | $36,211.51 |
DisclosureSEC source: 0001655962-25-000006 · form4-11192025_121121.xml · nonDerivative · entry 5 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,715 F3 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $8.545 to $9.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. Read SEC document |
| November 15, 2025 Filed Nov 19, 2025 00:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001655962-25-000006 · form4-11192025_121121.xml · derivative · entry 9 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| November 15, 2025 Filed Nov 19, 2025 00:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001655962-25-000006 · form4-11192025_121121.xml · derivative · entry 8 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| November 15, 2025 Filed Nov 19, 2025 00:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001655962-25-000006 · form4-11192025_121121.xml · derivative · entry 7 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| November 15, 2025 Filed Nov 19, 2025 00:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 1,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001655962-25-000006 · form4-11192025_121121.xml · derivative · entry 6 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| November 15, 2025 Filed Nov 19, 2025 00:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 6,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-25-000006 · form4-11192025_121121.xml · nonDerivative · entry 4 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| November 15, 2025 Filed Nov 19, 2025 00:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 6,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-25-000006 · form4-11192025_121121.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| November 15, 2025 Filed Nov 19, 2025 00:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-25-000006 · form4-11192025_121121.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| November 15, 2025 Filed Nov 19, 2025 00:02 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001655962-25-000006 · form4-11192025_121121.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F2 · balance_after: Includes 3,902 shares of Common Stock acquired by the Reporting Person between May 12, 2023 and November 14, 2025 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 162,000 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001655962-25-000004 · form4-11072025_111106.xml · derivative · entry 10 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,000 Underlying: Common Stock · 162,000 shares Expires 2035-01-14 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F7 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 162,000 | $0.00 Strike: $11.87 | $0.00 |
DisclosureSEC source: 0001655962-25-000004 · form4-11072025_111106.xml · derivative · entry 9 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 162,000 shares Expires 2035-01-14 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F7 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 15, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 162,000 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001655962-25-000004 · form4-11072025_111106.xml · derivative · entry 8 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,000 Underlying: Common Stock · 162,000 shares Expires 2034-01-04 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F6 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 162,000 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001655962-25-000004 · form4-11072025_111106.xml · derivative · entry 7 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 162,000 shares Expires 2034-01-04 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F6 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 5, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 116,000 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001655962-25-000004 · form4-11072025_111106.xml · derivative · entry 6 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,000 Underlying: Common Stock · 116,000 shares Expires 2033-01-16 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 116,000 | $0.00 Strike: $23.41 | $0.00 |
DisclosureSEC source: 0001655962-25-000004 · form4-11072025_111106.xml · derivative · entry 5 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 116,000 shares Expires 2033-01-16 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, commencing February 17, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 151,000 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001655962-25-000004 · form4-11072025_111106.xml · derivative · entry 4 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,000 Underlying: Common Stock · 151,000 shares Expires 2032-01-17 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 151,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001655962-25-000004 · form4-11072025_111106.xml · derivative · entry 3 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 151,000 shares Expires 2032-01-17 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, with 100% of the total shares vested on January 18, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | GrantStock Option (right to buy Common Stock) · Derivative | 497,667 | $0.00 Strike: $8.99 | $0.00 |
DisclosureSEC source: 0001655962-25-000004 · form4-11072025_111106.xml · derivative · entry 2 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 497,667 Underlying: Common Stock · 497,667 shares Expires 2031-05-25 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Disposition to issuerStock Option (right to buy Common Stock) · Derivative | 497,667 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001655962-25-000004 · form4-11072025_111106.xml · derivative · entry 1 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 497,667 shares Expires 2031-05-25 F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The options are fully vested. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 23:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 4,106 | $6.77 | $27,785.71 |
DisclosureSEC source: 0001415889-25-022386 · form4-08192025_110809.xml · nonDerivative · entry 5 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,000 F2 · kind: The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $6.65 to $6.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 23:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022386 · form4-08192025_110809.xml · derivative · entry 9 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,125 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 23:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022386 · form4-08192025_110809.xml · derivative · entry 8 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,625 Underlying: Common Stock · 6,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 23:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022386 · form4-08192025_110809.xml · derivative · entry 7 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 23:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 1,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022386 · form4-08192025_110809.xml · derivative · entry 6 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,375 Underlying: Common Stock · 1,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 23:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 6,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022386 · form4-08192025_110809.xml · nonDerivative · entry 4 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 23:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 6,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022386 · form4-08192025_110809.xml · nonDerivative · entry 3 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 23:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022386 · form4-08192025_110809.xml · nonDerivative · entry 2 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 23:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | Exercise / conversionCommon Stock | 1,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-022386 · form4-08192025_110809.xml · nonDerivative · entry 1 York Charles N II · CIK 0001655962 · COO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.